In order to stop MS in its tracks, restore what has been lost and ultimately end MS forever, the Society pursues all promising research paths and collaborates with investigators and key stakeholders worldwide to accelerate progress and realize future solutions for people with MS.
Alliance Meeting Inspires Hope for Fallon Wynne Way and Numerous Society Supporters
|Fallon Wynne Way presents $210,550 gift to Society and Alliance leadership in San Francisco
“Although answers to progressive MS didn’t come fast enough to benefit my mother,” says Fallon Wynne Way, whose mother Dee Wynne passed away in 2014, “I now have hope and confidence that we are closer than ever before to answers that will change the lives of everyone living with progressive MS today.”
Fallon, who is President and Chairman of the Yellow Rose Gala Foundation in Dallas, TX, was just one of nearly 60 supporters affected by MS that attended last month’s Second Scientific Congress of the International Progressive MS Alliance in San Francisco. During this pivotal two-day meeting, over 125 of the world’s leading MS experts convened to assess the challenges to progressive MS treatments and to chart a new course for speeding future solutions.
Led by the National MS Society and a host of other MS Societies across the globe, the International Progressive MS Alliance was formed in 2012 with the goal of speeding treatments to people living with progressive MS. For the first time ever, these countries are now pooling their talent and resources to drive collaboration and fund the most promising research on progressive MS, without regard for geographic borders.
“To know that the global MS community is now united in pursuing solutions for people with progressive MS, gives me great confidence to support this groundbreaking work,” said Fallon, whose foundation recently raised over $200,000 to support the Alliance through the Yellow Rose Gala Foundation, an influential charity event in Dallas founded by Fallon’s mother Dee that has raised millions for MS research over the years.
As with past Alliance meetings, the discussion and ideas stimulated in San Francisco combined with the generosity of Fallon and others who have committed their support, will focus the research community on the key questions facing progressive MS and will continue to drive treatment progress momentum.
Antihistamine Shows Evidence of Stimulating Myelin Repair in Small Phase II Trial
Recent results from a small phase II clinical trial led by Dr. Ari Green, a Society-funded researcher from the University of California, San Francisco, showed that the oral antihistamine, clemastine, modestly improved the transmission of electrical signals in the optic nerve in participants with MS who had optic nerve damage. The improved transmission indicates that nerve-insulating myelin was repaired along the nerve pathways.
Clemastine was identified as having possible myelin-repairing properties through innovative research conducted by National MS Society-funded researcher Jonah Chan, PhD, who went on to become the first recipient of the Barancik Prize
for Innovation in MS Research for this pioneering work.
Doses of the antihistamine in this trial exceeded the maximum recommended for over-the-counter use. Clemastine affects a range of targets in the body, and involves the risk for side effects such as extreme fatigue, particularly at increased dosages.
This team is planning an additional trial to further determine the safety and effectiveness of clemastine, as well as studies to develop modified versions of clemastine that may enhance myelin repair and cause fewer side effects.
To learn more about the clemastine trial and other exciting research findings reported at April’s American Academy of Neurology Meeting in Vancouver, BC, visit the Research News feed
on the Society’s website.
Society Commits Over $25 Million in Recent Research Investments
Thanks to the generous support of donors like you, the Society recently committed over $25 million to support an expected 60 new MS research projects. This financial commitment is the latest in the Society’s relentless research efforts to move us closer to a world free of MS, and part of a projected investment of $52 million in 2016 alone to support more than 380 new and ongoing studies around the world.
See Your Investment in Action
Witness how the Society works to shape the MS research landscape by participating in the Society’s next Research Programs Advisory Committee Meeting (RPAC) taking place June 23-24 in Washington, D.C.
Contact Heather Lee at email@example.com
or 303-698-6140 to learn more about this opportunity.